Press releaseACCESS Newswire
Exousia Pro
MAJI · OTC
$0.0038+$0.0004 (+11.76%)TodayMarket closed ·
Prev close $0.0034
Latest news
- Press releaseACCESS Newswire
NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology
- Press releaseACCESS Newswire
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
- Press releaseACCESS Newswire
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
- Press releaseACCESS Newswire
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
- Press releaseGlobe Newswire
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
- Press releaseGlobe Newswire
NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
- Press releaseGlobe Newswire
NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University
- Press releaseGlobe Newswire
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
- Press releaseGlobe Newswire
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
- Press releaseGlobe Newswire
NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test
- Press releaseGlobe Newswire
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
- Press releaseGlobe Newswire
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
- Press releaseGlobe Newswire
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
- Press releaseACCESS Newswire
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
- Press releaseACCESS Newswire
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
- Press releaseACCESS Newswire
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
- Press releaseACCESS Newswire
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
- Press releaseACCESS Newswire
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
- Press releaseACCESS Newswire
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
- Press releaseACCESS Newswire
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
- Press releaseACCESS Newswire
Exousia Pro Reports Positive Outcome in Legal Proceeding
- Press releaseACCESS Newswire
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
- Press releaseACCESS Newswire
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
- Press releaseACCESS Newswire
Exousia Pro Creates New Subdivisions
- Press releaseACCESS Newswire
Exousia Pro Files Reg A.
- Press releaseACCESS Newswire
Exousia Pro Expands its Scientific Advisory Board
- Press releaseACCESS Newswire
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
- Press releaseACCESS Newswire
Exousia Pro Has Appointed Matthew Dwyer As Its New President
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.